These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 22155904)
1. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991 [TBL] [Abstract][Full Text] [Related]
3. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients. Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254 [TBL] [Abstract][Full Text] [Related]
5. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540 [TBL] [Abstract][Full Text] [Related]
6. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients. Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164 [TBL] [Abstract][Full Text] [Related]
7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M; Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Reischig T; Hribova P; Jindra P; Hes O; Bouda M; Treska V; Viklicky O J Am Soc Nephrol; 2012 Sep; 23(9):1588-97. PubMed ID: 22917575 [TBL] [Abstract][Full Text] [Related]
9. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir. Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766 [No Abstract] [Full Text] [Related]
11. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Kacer M; Kielberger L; Bouda M; Reischig T Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients. Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140 [TBL] [Abstract][Full Text] [Related]
13. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762 [TBL] [Abstract][Full Text] [Related]
14. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956 [TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964 [TBL] [Abstract][Full Text] [Related]
16. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095 [TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients. Wéclawiak H; Kamar N; Mengelle C; Guitard J; Esposito L; Lavayssière L; Cointault O; Ribes D; Rostaing L J Med Virol; 2008 Jul; 80(7):1228-32. PubMed ID: 18461614 [TBL] [Abstract][Full Text] [Related]